On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
Taiho Moves Araris’ ADC into PI for Lymphoma in US
Taiho Pharmaceutical and its Swiss unit Araris Biotech said on April 28 that the US FDA has completed its IND review for ARC-02, clearing the way for a PI dose-escalation trial of the antibody drug conjugate (ADC) in development for…
To read the full story
Related Article
BUSINESS
- MSD Set to Match Beyfortus Price for RSV Antibody Enflonsia if Added to NIP
November 12, 2026
- Takeda Files Zasocitinib for Three Psoriasis Indications in Japan
November 12, 2026
- Vital KSK Finds No Evidence of Customer Data Leak after Cyberattack
November 12, 2026
- Toho Bankrolls UK Biotech Developing Alzheimer’s Therapy
November 12, 2026
- Maruishi to Invest 300 Million Yen in Kringle Pharma
November 12, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…